← Evidence map

ArticleTranslational lung cancer research2026

Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study.

Min Jee Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study. | OpenQuestion